Send to

Choose Destination
Int J Clin Pharmacol Ther. 2017 Sep;55(9):746-752. doi: 10.5414/CP203025.

Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment



Sugammadex rapidly reverses moderate and deep rocuronium- or vecuronium-induced neuromuscular blockade at doses of 4 mg/kg and 2 mg/kg, respectively. Sugammadex is renally eliminated. This study evaluated the pharmacokinetics of sugammadex in subjects with renal impairment versus those with normal renal function.


This open-label, two-part, phase 1 study included adults with moderate (creatinine clearance (CL<sub>cr</sub>) 30 - < 50 mL/min) and severe (CL<sub>cr</sub> < 30 mL/min) renal impairment and healthy controls (CL<sub>cr</sub> ≥ 80 mL/min). A single intravenous (IV) bolus injection of sugammadex 4 mg/kg was administered into a peripheral vein over 10 seconds directly by straight needle in part 1 (n = 24; 8/group), and via an IV catheter followed by a saline flush in part 2 (n = 18; 6/group). Plasma concentrations of sugammadex were collected after drug administration. Due to dosing issues in part 1, pharmacokinetic parameters were determined for part 2 only. Safety was assessed throughout the study.


Pharmacokinetic data were obtained from 18 subjects. Mean sugammadex exposure (AUC<sub>0-∞</sub>) in subjects with moderate and severe renal impairment was 2.42- and 5.42-times, respectively, that of healthy controls. Clearance decreased and apparent terminal half-life was prolonged with increasing renal dysfunction. Similar C<sub>max</sub> values were observed in subjects with renal impairment and healthy controls. There were no serious adverse events.


Sugammadex exposure is increased in subjects with moderate and severe renal insufficiency due to progressively decreased clearance as a function of worsening renal function. Sugammadex 4 mg/kg was well tolerated in subjects with renal impairment, with a safety profile similar to that of healthy subjects. These results indicate that dose adjustment of sugammadex is not required in patients with moderate renal impairment; however, current safety experience is insufficient to support the use of sugammadex in patients with CL<sub>cr</sub> < 30 mL/min.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Dustri-Verlag Dr. Karl Feistle GmbH & Co. KG
Loading ...
Support Center